Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes mellitus

Current Diabetes Reports

Volumn 4, Issue 6, 2004, Pages 409-412

  Ram Ayyar, D ^a   Sharma, Khema R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE;

ASEPTIC MENINGITIS; CARDIOVASCULAR DISEASE; DEMYELINATING DISEASE; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; ELECTROMYOGRAPHY; HEADACHE; HUMAN; IMMUNOMODULATION; INCIDENCE; KIDNEY FAILURE; LUNG DISEASE; MOTOR DYSFUNCTION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL NEUROPATHY; PHYSICIAN; PLASMAPHERESIS; POLYRADICULONEUROPATHY; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SENSORY NEUROPATHY; THROMBOSIS;

EID: 12144283463     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0048-y     Document Type: Review

References (36)

1. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force [no authors listed]. Neurology 1991, 41:617-618.
2. Rotta FT, Sussman AT, Bradley WG, et al.: The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000, 173:129-139.
3. Van Doorn PA, Rossi F, Brand A, et al.: On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990, 29:57-64.
4. Frank MM, Basta M, Fries LF: The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992, 62(1 Pt 2): 82-S86.
5. Dalakas MC: Mechanisms of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998, 51(suppl : 2-S8.
6. Griffin JW, George R, Lobato C, et al.: Macrophage responses and myelin clearance during Wallerian degeneration: relevance to immune-mediated demyelination. J Neuroimmunol 1992, 40: 53-165.
7. Miyagi F, Horiuchi H, Nagata I, et al.: Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis. J Neuroimmunol 1997, 78:127-131.
8. Saoudi A, Hurez V, de Kozak Y, et al.: Human immunogloblin preparations for intravenous use (IVIg) prevent experimental autoimmune uveoretinitis. Int Immunol 1993, 5: 559-1567.
9. Anderson CL: Human IgG Fc receptors. Clin Immunol Immunopathol 1989, 53(2 Pt 2):S63-S71.
10. Boulton AJM, Angus E, Ayyar DR, et al.: Diabetic thoracic polyradiculopathy presenting as an abdominal swelling. BMJ 1984, 289:798-799.
11. Krendel DA, Skehan ME: Patients with type I diabetes mellitus are predisposed to chronic demyelinating polyneuropathy. Neurology 1998, 50(suppl 4):A333.
12. Simpson DA: Diabetic autoimmune neuropathies: responsive to intravenous gammaglobulin. Muscle Nerve 1997, 20: 069-1070.
13. Cross J, Sharma KR, Ayyar DR, et al.: Demyelinating neuropathy in-patients with type II diabetes. Neurology 1999, 52(suppl):A85.
14. Stewart JD, McKelvey R, Durcan L, et al.: Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci 1996, 142:59-64.
15. Gorson KC, Ropper AH, Adelman LS, Weinberg DH: Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000, 23:37-43.
16. Cornblath DR, Drachman DB, Griffin JW: Demyelinating motor neuropathy in patients with diabetic polyneuropathy [abstract]. Ann Neurol 1987, 22:126.
17. Baruah JK: Diabetic demyelinating polyneuropathy and responsive to high doses of methylprednisone and immunoglobulin therapies [abstract]. Muscle Nerve 1998, 21:1607.
18. Engel WK, Prentice AF: Some polyneuropathies (PNS) in insulin-requiring adult-onset diabetes (IRAOD) can benefit remarkably from antidysimmune treatment. Neurology 1993, 43: 255-A256.
19. Barreira A, Marques W, Flores-Vieira C, et al.: Chronic inflammatory demyelinating polyneuropathy with only sensory symptoms (CIDPS): electroneurophysiological and morphological aspects and association with diabetes mellitus. Proc Periph Nerve Soc 1997, 115.
20. Gorson CG, Allen G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997, 48:321-328.
21. Menkes D, Hood D, Ballesteros R, Williams D: Root stimulation improves the detection of acquired demyelinating polyneuropathies. Muscle Nerve 1998, 21:298-308.
22. Behse F, Buchthal F, Carlsen F: Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1977, 40:1072-1082.
23. Abu-Shakra SR, Cornblath DR, Avila OL, et al.: Conduction block in diabetic neuropathy. Muscle Nerve 1991, 14:858-862.
24. Tjon-A-Tsien A, Lemkes H, Callenbach P, Van Dijk J: CMAP variation over a length of nerve in diabetic neuropathy. Muscle Nerve 1995, 18:907-909.
25. Sharma KR, Cross J, Ayyar DR, et al.: Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002, 59:751-757.
26. Younger DS, Rosoklija G, Hays AP, et al.: Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve 1996, 19: 22-727.
27. Krendel DA, Zacharias A, Younger DS: Autoimmune diabetic neuropathy. Neurol Clin 1997, 15:959-971.
28. Krendel DA, Castigan DA, Hopkins LC: Successful treatment of neuropathies in-patients with diabetes mellitus. Arch Neurol 1995, 52:1053-1061.
29. Sharma KR, Cross J, Farronay O, et al.: Demyelinating neuropathy in diabetes. Arch Neurol 2002, 59: 58-765.
30. Miyasaki H, Hasegawa O, Mori I, et al.: Incidence of diabetic neuropathy which fulfills electrophysiological criteria of CIDP [in Japanese]. No To Shinkei 1999, 51:415-418.
31. Mitchell GW, William GS, Bosch EP, Hart MN: Class II antigen expression in peripheral neuropathies. J Neurol Sci 1991, 102:170-176.
32. Shigeta H, Yamaguchi M, Nakano K, et al.: Serum auto-antibodies against sulphatide and phospholipid in NIDDM patients with diabetic neuropathy. Diabetes Care 1997, 20: 896-1899.
33. Milicevic Z, Newlon P, Pittenger G, et al.: Anti-ganglioside GM1 antibody and distal symmetric "diabetic polyneuropathy" with dominant motor features. Diabetologia 1997, 40:1364-1365.
34. Zanone M, Banga J, Peakman M, et al.: An investigation of antibodies to nerve growth factor in diabetic autonomic neuropathy. Diabet Med 1994, 11:78083.
35. Sensi M, Pricci F, Andreani D, Di Mario U: Advanced non-enzymatic glycation end products: their relevance to aging and pathogenesis of late diabetic complications. Diabetes Res 1991, 16:1-9.
36. Ono Y, Aoki S, Ohnishi K, et al.: Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 1998, 41:131-137.